Rivus reveals data to back up muscle-sparing claims of phase 2 obesity drug

Rivus Pharmaceuticals has unveiled the data behind its phase 2 obesity win in heart failure patients, showing that the candidate can indeed help patients reduce weight while they retain muscle.